On March 10, 2023 Abcam plc (Nasdaq: ABCM) ("Abcam" or the "Company"), a global leader in the supply of life science research tools, reported its results for the year ended 31 December 2022 at 7.00 a.m. ET on 20 March 2023 (Press release, Abcam, MAR 10, 2023, View Source [SID1234628563]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. ET that same day (details below).
To access the webcast, please use the following link:
The press release and the live audio webcast will also be available in the investor section of Abcam’s corporate website at corporate.abcam.com/investors/reports-presentations/. An archive will be available after the call at that same address.
For further information please contact:
Abcam
Tommy Thomas, CPA, Vice President, Investor Relations
+1 617 577 4205